Depression, the most frequent psychiatric disorder following ischaemic stroke, negatively
affects survivals' functional outcome, response to rehabilitation and quality of life …

Background Duloxetine is a balanced serotonin and noradrenaline reuptake inhibitor
licensed for the treatment of major depressive disorders, urinary stress incontinence and the …

Duloxetine is a serotonin-norepinephrine reuptake inhibitor approved for the treatment of
patients affected by major depressive disorder (MDD), generalized anxiety disorder (GAD) …

Introduction Work-related disability and productivity loss in Major Depressive Disorder
(MDD) are critical determinants of patient quality of life and contribute significantly to the …

Objective The goal of this meta-analysis was to quantify the risk of dry mouth associated with
commonly prescribed antidepressant agents and examine the potential implications of …

Major depressive disorder (MDD) and other mental health issues pose a substantial burden
on the workforce. Approximately half a million Canadians will not be at work in any week …

Background Painful physical symptoms (PPS) are highly prevalent in patients with major
depressive disorder (MDD). Presence of PPS in depressed patients are potentially …

OBJECTIVE: The objective of this study was to investigate the association between pain and
mood and anxiety disorders, as well as psychological symptoms, in a population-based …

Duloxetine has been increasingly administered, but the associated cardiovascular adverse
event risk is not clearly understood. Therefore, we identified the association between …

Background Pain is a common symptom in patients with depressive disorders, which, if
present, worsens the prognosis. However, there is little empirical knowledge of the …